Physician profile
Neel R Desai
NPI 1609957786
$1,001,169.70
in general payments reported to CMS, 2019-2025
35 companies · $192K in 2025
The $192K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $226K · 2020: $78K · 2021: $118K · 2022: $54K · 2023: $146K · 2024: $186K · 2025: $192K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $334K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $24K · Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $334,471.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,464.95 |
| Travel and Lodging | $23,748.97 |
| Food and Beverage | $11,005.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,650.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $398,744.03 | 2019-2025 | |
| Alcon Vision LLC | $204,590.26 | 2019-2025 | Clareon, Hydrus Microstent, Voyager Dslt |
| Sight Sciences, INC. | $89,105.65 | 2019-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $53,672.27 | 2022-2025 | Envista Mx60 Iol, Trulign Iol, Stellaris Elite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49,607.57 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $36,316.00 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $27,576.83 | 2019-2021 | |
| Dompe US, INC. | $26,574.38 | 2020-2025 | Oxervate |
| Nordic Pharma, INC. | $20,235.66 | 2024-2025 | Lacrifill, Lacrifill |
| Glaukos Corporation | $18,084.11 | 2022-2025 | Epioxa, Ce-Marked Kxla System, Kxl System |
| Alcon Research LLC | $15,631.00 | 2019-2025 | Acrysof Iq Panoptix Uv Iol, Clareon, Acrysof Iq Vivity |
| Eyevance Pharmaceuticals LLC | $10,580.20 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $10,000.02 | 2019-2024 | Catalys System, Ifs Advanced Femtosec Laser, Compact Intuitiv |
| Novartis Pharmaceuticals Corporation | $9,597.68 | 2019-2020 | |
| Shire North American Group INC | $9,152.33 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis, INC | $8,410.52 | 2019 | |
| Abbvie INC. | $5,311.06 | 2024-2025 | |
| Carl Zeiss Meditec, INC. | $4,400.00 | 2025 | Callisto Eye, Visumax, Atlas 500 |
| Eyepoint US, INC. | $1,356.49 | 2019 | |
| Omeros Corporation | $559.26 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $368.73 | 2021-2025 | |
| Topcon Healthcare, INC. | $289.95 | 2025 | |
| Horizon Therapeutics Plc | $172.47 | 2020-2022 | |
| Harrow Eye, LLC | $143.95 | 2024-2025 | Iheezo, Triesence |
| New World Medical,INC. | $130.14 | 2024-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Carl Zeiss Meditec Cataract Technology INC. | $90.53 | 2023-2024 | |
| Rxsight INC | $88.97 | 2023-2024 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Lensar, INC. | $64.48 | 2019 | |
| Amgen INC. | $62.39 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $59.27 | 2024 | Purified Cortrophin Gel |
| Coopervision INC. | $54.35 | 2020 | |
| Allergan, INC. | $46.20 | 2019-2020 | |
| Oyster Point Pharma, INC. | $41.23 | 2022-2024 | Ryzumvi, Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $31.63 | 2025 | Xdemvy |
| Teva Pharmaceuticals USA, INC. | $20.09 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$12,600.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.